Can Fite Valuation
| CANF Stock | USD 1.58 0.06 3.95% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Can Fite Biopharma shows a prevailing Real Value of $5.51 per share. The current price of the firm is $1.58. Our model approximates the value of Can Fite Biopharma from analyzing the firm fundamentals such as Return On Equity of -1.58, operating margin of (12.96) %, and Shares Outstanding of 6.1 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Can Fite's valuation include:
Price Book 3.8856 | Enterprise Value 4.3 M | Enterprise Value Ebitda 0.0965 | Price Sales 14.4413 | Forward PE 2.9665 |
Undervalued
Today
Please note that Can Fite's price fluctuation is relatively risky at this time. Calculation of the real value of Can Fite Biopharma is based on 3 months time horizon. Increasing Can Fite's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Can stock is determined by what a typical buyer is willing to pay for full or partial control of Can Fite Biopharma. Since Can Fite is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Can Stock. However, Can Fite's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.58 | Real 5.51 | Target 17.33 | Hype 1.62 |
The real value of Can Stock, also known as its intrinsic value, is the underlying worth of Can Fite Biopharma Company, which is reflected in its stock price. It is based on Can Fite's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Can Fite's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Can Fite Biopharma helps investors to forecast how Can stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Can Fite more accurately as focusing exclusively on Can Fite's fundamentals will not take into account other important factors: When choosing an evaluation method for Can Fite Biopharma, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Can Fite Cash |
|
Can Valuation Trend
Comparing Can Fite's enterprise value against its market capitalization is a good way to estimate the value of Can Fite Biopharma uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Can Fite Total Value Analysis
Can Fite Biopharma is currently estimated to have valuation of 4.31 M with market capitalization of 9.63 M, debt of 40 K, and cash on hands of 12.77 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Can Fite fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.31 M | 9.63 M | 40 K | 12.77 M |
Can Fite Investor Information
The book value of the company was currently reported as 0.0. The company recorded a loss per share of 2.6. Can Fite Biopharma last dividend was issued on the 10th of May 2019. The entity had 1:10 split on the 9th of January 2023. Based on the measurements of operating efficiency obtained from Can Fite's historical financial statements, Can Fite Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Can Fite Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Can Fite has an asset utilization ratio of 7.44 percent. This implies that the Company is making $0.0744 for each dollar of assets. An increasing asset utilization means that Can Fite Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Can Fite Ownership Allocation
Almost 92.0 percent of Can Fite outstanding shares are held by general public with 8.0 % by other corporate entities.Can Fite Profitability Analysis
The company reported the previous year's revenue of 743 K. Net Loss for the year was (7.63 M) with profit before overhead, payroll, taxes, and interest of 810 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Can Fite's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Can Fite and how it compares across the competition.
About Can Fite Valuation
The stock valuation mechanism determines Can Fite's current worth on a weekly basis. Our valuation model uses a comparative analysis of Can Fite. We calculate exposure to Can Fite's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Can Fite's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 743 K | 1.1 M | |
| Pretax Profit Margin | (10.27) | (10.79) | |
| Operating Profit Margin | (11.03) | (11.58) | |
| Net Loss | (10.27) | (10.79) |
Can Fite Growth Indicators
Investing in growth stocks can be very risky. If the company such as Can Fite does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 4.3 M | |
| Forward Price Earnings | 2.9665 |
Can Fite Current Valuation Indicators
Valuation refers to the process of determining the present value of Can Fite Biopharma and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Can we look at many different elements of the entity such as Can's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Can Fite, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Can Fite's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Can Fite's worth.Complementary Tools for Can Stock analysis
When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |